



Dr. Ralf Kettenhofen is an employee of the Fraunhofer Institute for Biomedical Engineering IBMT with responsibilities in business development and as Senior Scientist in pluripotent stem cell sciences.

He is a chemist by training and received his PhD from the Rheinische-Friedrich-Wilhlems University in Bonn in 2000. After one year as a postdoctoral fellow Ralf joined the stem cell biotech company Axiogenesis AG, which later became Ncardia AG, and he worked there for 18 years as a Senior Scientist, Head of Laboratory, Head of Production and Product Manager of pluripotent stem cell-derived

cardiomyocytes before he joined Fraunhofer IBMT in 2019.

Since 2013 Ralf is a member of the HESI Cardiac Safety Committee and participated in the CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative in which human pluripotent stem cell-derived cardiomyocytes were successfully validated for the use in safety pharmacological studies.